vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v20i5.2322vsp-2751Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEЛечение среднетяжелого и тяжелого псориаза у детей: новые возможности генно-инженерной биологической терапииManagement of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugshttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва; Белгород.

Moscow; Belgorod.

https://orcid.org/0000-0002-1450-4942БакулевА. Л.BakulevAndrey L.

Саратов.

Saratov.

https://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurachkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей; профессор кафедры дерматовенерологии и косметологии ЦГМА; профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова.119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.Тел.: +7 (495) 967-14-20

Moscow.

m_nn2001@mail.ruhttps://orcid.org/0000-0001-6531-3073НамЛ. Н.NamLyudmila N.

Саратов.

Saratov.

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва.

Moscow.

НИИ педиатрии и охраны здоровья детей ЦКБ РАН; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова; Белгородский государственный национальный исследовательский университетРоссияResearch Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod National Research UniversityRussian FederationСаратовский государственный медицинский университет им. В.И. РазумовскогоРоссияSaratov State Medical University n.a. V.I. RazumovskyRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children's HealthRussian FederationСаратовский медицинский университет «Реавиз»РоссияMedical University ReavizRussian Federation202106112021205446450Copyright © Намазова-Баранова Л.С., Бакулев А.Л., Мурашкин Н.Н., Нам Л.Н., Иванов Р.А., 20212021Намазова-Баранова Л.С., Бакулев А.Л., Мурашкин Н.Н., Нам Л.Н., Иванов Р.А.Namazova-Baranova L.S., Bakulev A.L., Murachkin N.N., Nam L.N., Ivanov R.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2751

В статье показана ключевая роль IL-17 в патогенезе псориаза и возможность его блокирования секукинумабом — препаратом на основе моноклональных антител. Представлен обзор международных рандомизированных исследований клинической эффективности и безопасности генно-инженерного биологического препарата секукинумаб у детей и подростков, больных псориазом. В сроки лечения от 12 до 52 нед секукинумаб демонстрирует высокую терапевтическую эффективность в отношении тяжести псориаза и площади поражения кожи, благоприятное влияние на качество жизни детей и подростков по данным динамической оценки индексов PASI, IGA 0/1 mod 2011, опросника CDLQI. Профиль безопасности препарата секукинумаб у детей оценивается как благоприятный и сопоставимый с таковым при применении препарата у взрослых.

The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab. The review of international randomized trials on clinical efficacy and safety of genetically engineered biologic drug secukinumab in children and adolescents with psoriasis is presented. During treatment periods of 12 to 52 weeks, secukinumab has shown high therapeutic efficacy for psoriasis severity and skin lesion areas and has improved quality of life of children and adolescents according to dynamic assessments of PASI, IGA 0/1 mod 2011 indices, CDLQI questionnaire. The safety profile of secukinumab in children is estimated as favorable and comparable to using it in adults.

псориаздетитерапиягенно-инженерные биологические препаратысекукинумабэффективностьбезопасностьpsoriasischilfrentherapygenetically engineered biologic drugssecukinumabefficacysafetyНе указан.Not specified.ReferencesКубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Итоги 2018 года // Вестник дерматологии и венерологии. — 2019. — Т. 95. — № 4. — С. 8-23.Kubanov AA, Bogdanova EV. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik Dermatologii i Venerologii. 2019;95(4):8-23. (In Russ.)Dhar S, Banerjee R, Agrawal N, Chatterjee S, Malakar R. Psoriasis in children: An insight. Indian J Dermatol. 2011;56:262-265.Dhar S, Banerjee R, Agrawal N, Chatterjee S, Malakar R. Psoriasis in children: An insight. Indian J Dermatol. 2011;56:262-265.Silverberg NB. Update on pediatric psoriasis. Cutis. 2015;95(3):147-152.Silverberg NB. Update on pediatric psoriasis. Cutis. 2015;95(3):147-152.de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clin Dermatol. 2016;34(6):717-723.de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clin Dermatol. 2016;34(6):717-723.Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, Folster-Holst R, Gerdes S, Hamm H, Hoger P Horneff G, von Kiedrowski R, Philipp S, Pleimes M, Schlager M, Schuster V, Staubach P Weberschock T, Werner RN, Nast A, Sticherling M. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 1. J Dtsch Dermatol Ges. 2019;17(8):856-870.Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, Folster-Holst R, Gerdes S, Hamm H, Hoger P Horneff G, von Kiedrowski R, Philipp S, Pleimes M, Schlager M, Schuster V, Staubach P Weberschock T, Werner RN, Nast A, Sticherling M. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 1. J Dtsch Dermatol Ges. 2019;17(8):856-870.Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18:797-811.Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18:797-811.Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384.Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384.Rendon A, Schakel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. Published 2019 Mar 23. doi: 10.3390/ijms20061475Rendon A, Schakel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. Published 2019 Mar 23. doi: 10.3390/ijms20061475Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390.Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390.Bovenschen HJ, Van de Kerkhof PC, Van Erp PE, et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology. 2011;131:1853-1860.Bovenschen HJ, Van de Kerkhof PC, Van Erp PE, et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology. 2011;131:1853-1860.Nestle F, Kaplan DH, Barcer J. Psoriasis. N Engl J Med. 2009;361:496-509.Nestle F, Kaplan DH, Barcer J. Psoriasis. N Engl J Med. 2009;361:496-509.Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.Eisert L, Augustin M, et al. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 2. J Dtsch Dermatol Ges. 2019;17(9):959-973.Eisert L, Augustin M, et al. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 2. J Dtsch Dermatol Ges. 2019;17(9):959-973.Dogra S, Mahajan R. Biologics in pediatric psoriasis — efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9-16.Dogra S, Mahajan R. Biologics in pediatric psoriasis — efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9-16.Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Systematic review and economic evaluation. Health Technol Assess. 2017;21(64):1-244.Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Systematic review and economic evaluation. Health Technol Assess. 2017;21(64):1-244.Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434-442.Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434-442.Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. N Engl J Med. 2014;371:326-338.Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. N Engl J Med. 2014;371:326-338.Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy. 2020;13:3.Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy. 2020;13:3.Augustin M, Jullien D, Martin A, Peralta C. RWE of secukinumab in psoriasis treatment. JEADV. 2020;34:1174-1185. doi: 10.1111/jdv.16180Augustin M, Jullien D, Martin A, Peralta C. RWE of secukinumab in psoriasis treatment. JEADV. 2020;34:1174-1185. doi: 10.1111/jdv.16180Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; October 2020. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis (accessed: 20.10.2021).Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; October 2020. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis (accessed: 20.10.2021).Инструкция медицинскому применению препарата Козэнтикс, 2021. Available from: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2021-02-18_Cosentyx_sol_NPIv0_full.pdf (accessed: 20.10.2021).Инструкция медицинскому применению препарата Козэнтикс, 2021. Available from: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2021-02-18_Cosentyx_sol_NPIv0_full.pdf (accessed: 20.10.2021).Magnolo N, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021:S0190-9622(21)02509-3. doi: 10.1016/j.jaad.2021.08.066Magnolo N, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021:S0190-9622(21)02509-3. doi: 10.1016/j.jaad.2021.08.066Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E. Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2020 Oct 17.Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E. Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2020 Oct 17.Федеральные клинические рекомендации. Псориаз. Москва, 2020. Available from: https://cr.minzdrav.gov.ru/#!/recomend/866Федеральные клинические рекомендации. Псориаз. Москва, 2020. Available from: https://cr.minzdrav.gov.ru/#!/recomend/866Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opinion on Biological Therapy. 2020;20(2):173-182. doi: 10.1080/14712598.2020.1708897Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opinion on Biological Therapy. 2020;20(2):173-182. doi: 10.1080/14712598.2020.1708897Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 2019;21(1):111. doi: 10.1186/s13075-019-1882-2Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 2019;21(1):111. doi: 10.1186/s13075-019-1882-2

The authors declare that there are no conflicts of interest present.